211 results
The primary objectives of this study are:1. To assess the ideas and attitudes of patients with metastatic cancer about continuation of (another line of) chemotherapy. 2. To assess how patients experience a discussion about the last phase of life and…
* The primary objective of this study is:- the study of the response rate and the macroscopic and microscopic response charactheristics of neo-adjuvant chemotherapy of patients with peritoneal carcinomatosis (PC) of colorectal origin. * Secundary…
The primary objective for this study is:• To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response toAvastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full courseof treatment is completedThe…
Primary objectives:- To study the potential interaction of budesonide on the plasma exposure of cabazitaxelSecondary objectives:- To test the safety of concomitantly administrating cabazitaxel and budesonide in terms of potential side effects
To compare the diagnostic performance (sensitivity and specificity) of 18F NaF PET/CT in comparising to 99mTc MDP bonescintigraphy in a cohort of patients with newly diagnosed prostate cancer at high risk of developing skeletal metastases and in…
To compare the diagnostic performance of new lymph node staging methods for prostate cancer (dwMRI fused with 18F-Choline PET-CT) with the current gold standard of staging, the extended pelvic lymph node dissection (ELND)
To detect changes in multiple [18F]fluorodeoxyglucose positron emission tomography * computed tomography ([18F]FDG PET-CT) scans in one patient, test-retest variability needs to be determined, to know when an observed difference is due to a true…
Evaluation of the feasibility of sentinel node detection by PET-CT lymphoscintigraphy
The main objective of this pilot study is to determine the biological impact of treatment with targeted agents at the systemic and local tissue level in relation to toxicity.
1. The primary objectives of this phase I/II clinical trial is to demonstrate feasibility and evaluate the safety and toxicity of ACT plus vaccination according to CTCAE 4.0 criteria.2. Secondary objectives include the evaluation of the clinical…
Primary ObjectiveTo compare the objective response rate and overall surival of BMS-936558 versus docetaxel in subjects with squamous cell NSCLC after failure of prior platinum-based chemotherapySecondary ObjectivesTo compare the progression-free…
The primary objective of this study is to evaluate the ability of PET-MRI to detect LSR during the first year of follow-up after RFA treatment of CRLM as compared with ceCT and PET-CT. Standard reference will be histology (when available) or…
The main objective of the study is to determine time to progression of the primary malignancy (locally advanced or metastatic) in patients treated with ILuP and pulmonary metastasectomy. Secondary objectives are to assess pulmonary toxicity by…
The purpose of this clinical research study is to compare the effect of panitumumab to cetuximab (Erbitux®) in treating metastatic colorectal cancer in patients whose tumor contains the wild-type (unchanged) KRAS gene and who have previously been…
To assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.
The primary objective of this study is to investigate whether CYP3A phenotype, as measured with midazolam clearance, correlates with cabazitaxel clearance. Our secondary objective is to investigate whether this CYP3A phenotype outperforms BSA as a…
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
Primary objective: To establish whether concomitant therapy of trastuzumab, bevacizumab with paclitaxel (regimen A) and/or trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab, and paclitaxel at progression (regimen B…
To determine the optimal therapy for patients with pT1-2 pN0 oral and oropharyngeal cancer